Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s Keymed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback